Abbott Libre Duo 10 Day has received FDA authorization as the world’s first dual glucose-ketone biowearable, designed to alert people with diabetes to rising DKA risk while tracking glucose in real time.
Johnson & Johnson’s IMAAVY nipocalimab-aahu has received FDA approval as the first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), based on durable hemoglobin response data from the Phase 2/3 ENERGY study.
The historic Utebzi FDA approval introduces the first and only oral carbapenem antibiotic for adult patients suffering from complicated urinary tract infections (cUTIs), offering an effective outpatient treatment pathway to combat multidrug-resistant pathogens.
At the ADA 2026 Scientific Sessions, Novo Nordisk unveiled Phase 2 data for zenagamtide (amycretin), demonstrating exceptional blood sugar control and weight loss in type 2 diabetes.
Johnson & Johnson has shared late-breaking results from its Phase 2 JASMINE trial highlighting that nipocalimab achieves a sustained reduction in systemic lupus erythematosus (SLE) disease activity through 52 weeks.
The FDA has approved a label expansion for Johnson & Johnson’s TREMFYA® (guselkumab), cementing its position as the first IL-23 inhibitor with data showing it stops the progression of structural joint damage.
Accord BioPharma and Bio-Thera Solutions achieve a historic FDA approval for ImmGolis, the first interchangeable simponi biosimilar to reach the U.S. market.
Understanding how hantavirus spreads is the first critical step in protecting yourself and your family from a rare but highly dangerous respiratory disease. Whether you are cleaning out an old barn, sweeping a dusty attic, or opening up a long-closed summer cabin, knowing the risks associated with rodent-borne pathogens can quite literally save your life. Hantaviruses are primarily excreted in the urine, droppings, and saliva of infected wild rodents, and most human infections occur when these substances are disturbed and become airborne, allowing microscopic viral particles to be easily inhaled.
Eli Lilly has released historic long-term data from the Omvoh mirikizumab-mrkz clinical trials, proving that the IL-23p19 antagonist maintains high rates of “disease clearance” through four years of treatment.
The recent STELARA FDA approval provides a crucial new non-TNF biologic treatment option for children two years and older suffering from moderately to severely active Crohn’s disease.
